

RECEIVED
C.F.T.C.

2007 SEP 13 AM 9:51

OFFICE OF THE SECRETARIAT



20 South Wacker Drive
Chicago, IL 60606-7499
www.cme.com

312/930.1000 tel/
312/466.4410 fax

September 12, 2007

Mr. David Stawick
Office of the Secretariat
Commodity Futures Trading Commission
Three Lafayette Centre, 1155 21st Street, NW
Washington, DC 20581

RE: Exchange Certification of Listing Date and Contract Months for
Commodity Excess Return Futures (CERFs). Submitted per Sec.
5c(c)(1) of the CEA and Regulation §40.6(1) thereunder.
CME Submission # 07-77.

Dear Ms. Donovan:

Chicago Mercantile Exchange Group ("CME" or "the Exchange") hereby notifies the Commission of its intentions with respect to the launch date of, and contract months associated with, a battery of Commodity Excess Return Futures (CERFs) based on sub-indices drawn from the S&P GSCI[®] Excess Return Index ("S&P GSCI ER Index"). These include the S&P GS Energy ER, S&P GS Non-Energy ER, S&P GS Natural Gas ER and S&P GS Industrial Metals ER Indexes.¹

Specifically, the Exchange intends to list these contracts exclusively on the CME Globex[®] electronic trading platform on Sunday, October 14, 2007 for trade date Monday, October 15, 2007. Further, the Exchange will list a single contract month in October 2012 for each of these four contracts. Such listing of contract months is authorized per CME Rule 42902.A., Trading Schedule, that provides that "[f]utures contracts shall be scheduled for trading during such hours and for delivery in such months as may be determined by the Board of Directors."

The Exchange certifies that this action complies with the Commodity Exchange Act and the regulations thereunder.

¹ CME originally certified Commodity Excess Return Futures (CERFs) per Sec. 5c(c)(1) of the CEA and Regulation Sec. 40.6(a) thereunder via CME Submission #07-55 dated July 23, 2007.

Mr. David Stawick
September 12, 2007
Page 2 of 2

Please do not hesitate to contact John W. Labuszewski, Managing Director, Research & Product Development at 312-466-7469 or via e-mail at jlab@cmegroup.com or myself if any questions arise during the processing of this submission. We would be most appreciative if you could reference our CME Submission #07-77 on any future correspondence related to this submission.

Sincerely,

/S/ Stephen M. Szarmack
Director and Associate General Counsel